Yanyan Chi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yanyan Chi has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Feng Wang
Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
3 shared publications- Yan Sun
Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
3 shared publications Zhengzheng Shan
Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
3 shared publicationsHan Xu
Department of Breast Disease Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications- Qingxia Fan
Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
2 shared publications Yana Zhang
Department of Oncology The First Affiliated Hospital of Zhengzhou University Zhengzhou China
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Wiley in Medcomm – Biomaterials and Applications
- Vol. 5 (4)
Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy
Macrophages have emerged as central regulators of tissue homeostasis, inflammation, and regeneration, yet their remarkable phenotypic plasticity and functional heterogeneity pose substantial challenges for therapeutic modulation. This review provides a comprehensive synthesis of macrophage immunobiology and its translation into bioengineered material strategies for cancer immunotherapy, anti‐infective/inflammatory therapy, and tissue regeneration. We first delineate the ontogeny and functional specialization of tissue‐resident and tumor‐associated macrophage populations, the marker‐defined subpopulations revealed by single‐cell technologies, and the signaling networks that govern macrophage polarization. We further examine the complex crosstalk between macrophages and the microenvironment, encompassing interactions with tumor cells, fibroblasts, neutrophils, and T cells, as well as metabolic regulation by lactate, cAMP, exosomes, and trained immunity. Building on this mechanistic foundation, we systematically review bioengineered delivery platforms spanning nanoscale carriers, cell membrane‐coated biomimetic systems, surface‐functionalized particles, and macroscale hydrogels and scaffolds, emphasizing the bidirectional macrophage–material feedback that dictates therapeutic outcomes. Despite notable progress, challenges in macrophage heterogeneity, manufacturing scalability, and long‐term safety remain. We highlight emerging directions, including single‐cell and spatial transcriptomics‐guided design, trained immunity‐based strategies, and artificial intelligence‐driven material development, which together promise to accelerate the translation of macrophage‐targeting biomaterials from bench to bedside.
- 7 October 2026
- Published by Wiley in Medcomm – Biomaterials and Applications
- Vol. 5 (4)
Open AccessSynergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy
Macrophages have emerged as central regulators of tissue homeostasis, inflammation, and regeneration, yet their remarkable phenotypic plasticity and functional heterogeneity pose substantial challenges for therapeutic modulation. This review provides a comprehensive synthesis of macrophage immunobiology and its translation into bioengineered material strategies for cancer immunotherapy, anti‐infective/inflammatory therapy, and tissue regeneration. We first delineate the ontogeny and functional specialization of tissue‐resident and tumor‐associated macrophage populations, the marker‐defined subpopulations revealed by single‐cell technologies, and the signaling networks that govern macrophage polarization. We further examine the complex crosstalk between macrophages and the microenvironment, encompassing interactions with tumor cells, fibroblasts, neutrophils, and T cells, as well as metabolic regulation by lactate, cAMP, exosomes, and trained immunity. Building on this mechanistic foundation, we systematically review bioengineered delivery platforms spanning nanoscale carriers, cell membrane‐coated biomimetic systems, surface‐functionalized particles, and macroscale hydrogels and scaffolds, emphasizing the bidirectional macrophage–material feedback that dictates therapeutic outcomes. Despite notable progress, challenges in macrophage heterogeneity, manufacturing scalability, and long‐term safety remain. We highlight emerging directions, including single‐cell and spatial transcriptomics‐guided design, trained immunity‐based strategies, and artificial intelligence‐driven material development, which together promise to accelerate the translation of macrophage‐targeting biomaterials from bench to bedside.
- Open Access
- 21 March 2022
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (7) , 1905-1917
Apatinib inhibits tumour progression and promotes antitumour efficacy of cytotoxic drugs in oesophageal squamous cell carcinoma
Apatinib, a highly selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), inhibits the angiogenesis of tumours. The function and mechanism of apatinib in oesophageal squamous cell carcinoma (ESCC) remain unknown. In present study, we found that the development of ESCC in patients was controlled by treatment of combination of apatinib and a chemotherapeutic drug. Moreover, apatinib efficiently promotes cell apoptosis, inhibits cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and activity of the Akt/mTOR pathway in ESCC cells. Western blot analysis showed that apatinib significantly increased vimentin protein levels, decreased Bcl2, matrix metalloproteinase 9 (MMP9), E-cadherin, p-Akt and p-mTOR protein levels in ESCC cells. Furthermore, apatinib enhanced chemosensitivity of cytotoxic drugs paclitaxel (TAX), 5-fluorouracil (5-FU) and cisplatin (DDP) by upregulating expression of vimentin protein, and downregulating expression of Bcl2, MMP9 and E-cadherin protein in vitro. Compared with single-agent groups, the combination of apatinib with each chemotherapeutic drug significantly repressed tumour growth and angiogenesis through blocking the expression of Ki67 and VEGFR-2 in vivo. Taken together, apatinib efficiently inhibits cell growth through blocking Bcl2 and Akt/mTOR pathway, and suppresses metastasis via inhibiting MMP9 and EMT in ESCC cells. Apatinib promoted antitumour effect of chemotherapeutic agents through promoting cell apoptosis and inhibiting EMT and angiogenesis in ESCC.
- 21 March 2022
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (7) , 1905-1917
Open AccessApatinib inhibits tumour progression and promotes antitumour efficacy of cytotoxic drugs in oesophageal squamous cell carcinoma
Apatinib, a highly selective inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), inhibits the angiogenesis of tumours. The function and mechanism of apatinib in oesophageal squamous cell carcinoma (ESCC) remain unknown. In present study, we found that the development of ESCC in patients was controlled by treatment of combination of apatinib and a chemotherapeutic drug. Moreover, apatinib efficiently promotes cell apoptosis, inhibits cell proliferation, invasion, epithelial-mesenchymal transition (EMT) and activity of the Akt/mTOR pathway in ESCC cells. Western blot analysis showed that apatinib significantly increased vimentin protein levels, decreased Bcl2, matrix metalloproteinase 9 (MMP9), E-cadherin, p-Akt and p-mTOR protein levels in ESCC cells. Furthermore, apatinib enhanced chemosensitivity of cytotoxic drugs paclitaxel (TAX), 5-fluorouracil (5-FU) and cisplatin (DDP) by upregulating expression of vimentin protein, and downregulating expression of Bcl2, MMP9 and E-cadherin protein in vitro. Compared with single-agent groups, the combination of apatinib with each chemotherapeutic drug significantly repressed tumour growth and angiogenesis through blocking the expression of Ki67 and VEGFR-2 in vivo. Taken together, apatinib efficiently inhibits cell growth through blocking Bcl2 and Akt/mTOR pathway, and suppresses metastasis via inhibiting MMP9 and EMT in ESCC cells. Apatinib promoted antitumour effect of chemotherapeutic agents through promoting cell apoptosis and inhibiting EMT and angiogenesis in ESCC.
- Open Access
- 5 July 2019
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 23 (9) , 6295-6307
miR‐516a‐3p inhibits breast cancer cell growth and EMT by blocking the Pygo2/Wnt signalling pathway
MiR‐516a‐3p has been reported to play a suppressive role in several types of human tumours. However, the expression level, biological function and fundamental mechanisms of miR‐516a‐3p in breast cancer remain unclear. In the present study, we found that miR‐516a‐3p expression was down‐regulated and Pygopus2 (Pygo2) expression was up‐regulated in human breast cancer tissues and cells. Through analysing the clinicopathological characteristics, we demonstrated that low miR‐516a‐3p expression or positive Pygo2 expression was a predictor of poor prognosis for patients with breast cancer. The results of a dual luciferase reporter assay and Western blot analysis indicated that Pygo2 was a target gene of miR‐516a‐3p. Moreover, overexpression of miR‐516a‐3p inhibited cell growth, migration and invasion as well as epithelial‐mesenchymal transition (EMT) of breast cancer cells, whereas reduced miR‐516a‐3p expression promoted breast cancer cell growth, migration, invasion and EMT. Furthermore, we showed that miR‐516a‐3p suppressed cell proliferation, metastasis and EMT of breast cancer cells by inhibiting Pygo2 expression. We confirmed that miR‐516a‐3p exerted an anti‐tumour effect by inhibiting the activation of the Wnt/β‐catenin pathway. Finally, xenograft tumour models were used to show that miR‐516a‐3p inhibited breast cancer cell growth and EMT via suppressing the Pygo2/Wnt signalling pathway. Taken together, these results show that miR‐516a‐3p inhibits breast cancer cell growth, metastasis and EMT by blocking the Pygo2/ Wnt/β‐catenin pathway.
- 5 July 2019
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 23 (9) , 6295-6307
Open AccessmiR‐516a‐3p inhibits breast cancer cell growth and EMT by blocking the Pygo2/Wnt signalling pathway
MiR‐516a‐3p has been reported to play a suppressive role in several types of human tumours. However, the expression level, biological function and fundamental mechanisms of miR‐516a‐3p in breast cancer remain unclear. In the present study, we found that miR‐516a‐3p expression was down‐regulated and Pygopus2 (Pygo2) expression was up‐regulated in human breast cancer tissues and cells. Through analysing the clinicopathological characteristics, we demonstrated that low miR‐516a‐3p expression or positive Pygo2 expression was a predictor of poor prognosis for patients with breast cancer. The results of a dual luciferase reporter assay and Western blot analysis indicated that Pygo2 was a target gene of miR‐516a‐3p. Moreover, overexpression of miR‐516a‐3p inhibited cell growth, migration and invasion as well as epithelial‐mesenchymal transition (EMT) of breast cancer cells, whereas reduced miR‐516a‐3p expression promoted breast cancer cell growth, migration, invasion and EMT. Furthermore, we showed that miR‐516a‐3p suppressed cell proliferation, metastasis and EMT of breast cancer cells by inhibiting Pygo2 expression. We confirmed that miR‐516a‐3p exerted an anti‐tumour effect by inhibiting the activation of the Wnt/β‐catenin pathway. Finally, xenograft tumour models were used to show that miR‐516a‐3p inhibited breast cancer cell growth and EMT via suppressing the Pygo2/Wnt signalling pathway. Taken together, these results show that miR‐516a‐3p inhibits breast cancer cell growth, metastasis and EMT by blocking the Pygo2/ Wnt/β‐catenin pathway.
- 24 July 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 503 (4) , 2583-2589
ZKSCAN3 promotes breast cancer cell proliferation, migration and invasion
- 24 July 2018
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 503 (4) , 2583-2589
ZKSCAN3 promotes breast cancer cell proliferation, migration and invasion